Old Web
English
Sign In
Acemap
>
authorDetail
>
Jing Wu
Jing Wu
Boehringer Ingelheim
Pharmacology
Medicine
Lupus nephritis
Protease
Faldaprevir
3
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
FC 049A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS
2021
Nephrology Dialysis Transplantation
David Jayne
Richard Furie
Juanita Romero-Diaz
Hirofumi Amano
Kajohnsak Noppakun
Harold Michael Gomez
Rhona Recto
Valerie Belsack
Nora M. Fagan
Steven J. Padula
Ivette Revollo
Jing Wu
Sudha Visvanathan
Jürgen Steffgen
Show All
Source
Cite
Save
Citations (0)
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
2020
British Journal of Clinical Pharmacology
Tobias Litzenburger
Jürgen Steffgen
Ewald Benediktus
Fabian Müller
Armin Schultz
Elliott Klein
Meera Ramanujam
Christian Harcken
Alpana Gupta
Jing Wu
Sabrina Wiebe
Xiujiang Li
Mary Flack
Steven J. Padula
Sudha Visvanathan
Andreas Hünnemeyer
Jianan Hui
Show All
Source
Cite
Save
Citations (3)
Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants
2016
Journal of Pharmacy and Pharmacology
Jing Wu
Thomas Gießmann
Benjamin Lang
Mabrouk Elgadi
Fenglei Huang
Show All
Source
Cite
Save
Citations (2)
1